Capricor Therapeutics (NASDAQ:CAPR) Trading Down 2.9% – Here’s Why

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR) fell 2.9% during trading on Tuesday . The company traded as low as $13.61 and last traded at $13.72. 58,980 shares changed hands during trading, a decline of 95% from the average session volume of 1,196,164 shares. The stock had previously closed at $14.13.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on CAPR shares. Oppenheimer reaffirmed an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a research note on Monday, September 23rd. HC Wainwright restated a “buy” rating and issued a $77.00 price target on shares of Capricor Therapeutics in a research report on Thursday, November 14th. Maxim Group boosted their price objective on shares of Capricor Therapeutics from $12.00 to $25.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. Piper Sandler initiated coverage on shares of Capricor Therapeutics in a report on Monday, October 21st. They set an “overweight” rating and a $35.00 target price for the company. Finally, Cantor Fitzgerald lifted their target price on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $34.50.

Capricor Therapeutics Trading Down 2.5 %

The company’s 50 day simple moving average is $17.83 and its 200 day simple moving average is $10.40. The stock has a market capitalization of $626.12 million, a PE ratio of -12.99 and a beta of 3.98.

Hedge Funds Weigh In On Capricor Therapeutics

A number of large investors have recently modified their holdings of the company. Main Street Financial Solutions LLC lifted its stake in shares of Capricor Therapeutics by 37.5% during the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after purchasing an additional 7,500 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of Capricor Therapeutics during the 3rd quarter valued at about $133,000. Bank of New York Mellon Corp lifted its position in Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after acquiring an additional 9,040 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new position in Capricor Therapeutics in the 3rd quarter worth approximately $161,000. Finally, Sassicaia Capital Advisers LLC purchased a new position in Capricor Therapeutics in the 3rd quarter worth approximately $192,000. 21.68% of the stock is currently owned by hedge funds and other institutional investors.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.